MTOR and cancer: Consequently, mTOR kinase inhibitors targeting both mTORC1 and mTORC2 are considered promising anti‐cancer therapies and are being tested in clinical trials, in combination with radiation and chemotherapy (Zhao et al, 2017; Mecca et al, 2018).